AKT1 and non-Hodgkin lymphoma: To do that, we treated primary B-cells with the Akt inhibitors and sirolimus alone or in combination at a concentration where the combination was enough to reduce viability to about 50% in NHL cells (Figures 2A, 4A, 6A).